secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001683168-25-006641
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio advances Phase 1b skin cancer trial to 5th cohort; presents at conference
------------------------------------------------------------------------------

- Patients are now being treated in the 5th cohort of the ongoing Phase 1b clinical trial for skin cancer (PH-762).
- Phio Pharmaceuticals will present at H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025.
- CEO Robert Bitterman will deliver an update on the trial and discuss strategy and next steps for the PH-762 program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825006641/0001683168-25-006641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825006641/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-006641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer